BioMarin Pharmaceuticals has tasked Compass Healthcare with the redesign of its unbranded Phenylketonuria (PKU) community website, www.PKU.com. The new site is slated to launch during Q2 2009.
In order to reach the roughly 12,000 individuals diagnosed with PKU in the US, Compass hopes to foster online engagement within the PKU community. The new site will allow registered members to maintain blogs and create other content. Static content created by BioMarin is subject to review by a panel of community members, according to Kristin Keller, VP, client services, at Compass. The site will also offer recipes and a diet food wiki, notes Keller.
PKU is a genetic condition that prohibits the body from metabolizing phenylalanine (Phe), an amino acid.
PKU sufferers must avoid foods high in protein.
“The purpose of the PKU.com site is to provide the PKU community with support and resources to better manage their disease,” said Keller.
BioMarin markets Kuvan, a prescription treatment that lowers Phe levels in the bloodstream.